New And Updated Clinical Data On Merck & Co.’s KEYTRUDA (Pembrolizumab) To Be Presented At 18th World Conference On Lung Cancer
Published: Sep 29, 2017
Data to Include Findings from Studies Evaluating KEYTRUDA as Monotherapy, in Novel Combinations, and in Real-World Setting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, across multiple lung (thoracic) malignancies, including non-small cell lung cancer (NSCLC), will be presented at the 18th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan, Oct. 15-18. Results from studies in first-line NSCLC – updated overall survival findings from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA as a monotherapy (Abstract OA 17.06), and an encore of additional five months of follow-up from the randomized G cohort of the phase 2 KEYNOTE-021 trial evaluating KEYTRUDA in combination with pemetrexed/carboplatin (Abstract OA 17.01) – will be presented. Additional data in novel combinations and real-world evidence will also be shared.
Merck has an extensive research program in NSCLC and is currently advancing multiple registration-enabling studies with KEYTRUDA as monotherapy and in combination with other treatments. Notable abstracts featuring KEYTRUDA at the meeting include:
Merck Sponsored Abstracts:
- Abstract OA 17.06, Oral: Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS =50%. J. Brahmer. Wednesday, Oct. 18, 3:25-3:35 p.m. JST. Location: Room 301 + 302.
- Abstract P2.04-014, Poster Session: Computing the Impact of Immunotherapy on NSCLC landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR). G. Simon. Tuesday, Oct. 17, 9:30 a.m.-4:00 p.m. JST. Location: Exhibit Hall (Hall B + C).
- Abstract P1.01-050, Poster Session: Cost-effectiveness of PDL1 based test-and-treat strategy with pembrolizumab as the 1st line treatment for NSCLC in Hong Kong. H. H. Loong. Monday, Oct. 16, 9:30 a.m.-4:00 p.m. JST. Location: T Exhibit Hall (Hall B + C).
- Abstract OA 13.02, Oral: Distribution of PD-L1 Tumor Expression by Assay Type in Patients with Metastatic NSCLC (mNSCLC). V. Velcheti. Wednesday, Oct. 18, 11:10-11:20 a.m. JST. Location: Room 301 + 302.